Pfizer Beats Quarterly Estimates as Non-Covid Sales Offset Slump

The company now projects annual revenue between $60.5 billion and $62.5 billion, a slight adjustment from its previous guidance of $59.5 billion to $62.5 billion. Despite this optimism, the updated range suggests annual sales will remain largely flat or dip slightly compared to the $62.6 billion recorded in 2025. This transition reflects the sharp reduction in demand for pandemic-era products, with Pfizer lowering its full-year revenue target for the Covid-19 vaccine and the antiviral treatment Paxlovid to $4 billion, down from the earlier projection of $5 billion.

To bridge the gap left by declining Covid-related income and the expiration of patents on older drugs, the firm is aggressively pivoting toward its long-term development pipeline. Key to this strategy is the recent $10 billion acquisition of the obesity-focused biotech firm Metsera. Investors are currently tracking upcoming data releases, specifically regarding a combination regimen featuring the company’s GLP-1 injection and an experimental amylin asset, which represent the next phase of Pfizer's growth strategy.